跳至主要内容
临床试验/NCT01832168
NCT01832168已完成不适用

A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.

MiMedx Group, Inc.2 个研究点 分布在 1 个国家目标入组 34 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
34
试验地点
2
主要终点
The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.

研究概览

简要总结

The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic prostatectomies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Clinically localized prostate cancer with Gleason score 6 or 7
  • SHIM Score greater than or equal to 16 in the absence of medication
  • Feasibility to perform unilateral or bilateral nerve sparing RALP

排除标准

  • Clinically locally advanced cancer and/or with Gleason score 8 or
  • Difficulty performing nerve sparing RALP.
  • Prior surgery at the site.
  • Site exhibits clinical signs and symptoms of infection.
  • SHIM score at screening <
  • Current use of anticoagulant medication including Coumadin, Plavix, etc.
  • Has had "salvage prostatectomy" - patients who failed prior therapies including external radiation therapy, cryotherapy, etc.
  • Has prior radiation therapy treatment at the site.
  • Prior hormonal therapy such as Lupron or oral anti-androgens.
  • Non-mobile, i.e. not ambulatory or bed ridden.
  • The presence of comorbidities that can be confused with or can exacerbate the condition including:
  • advanced atherosclerotic vascular disease
  • Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  • Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
  • Unable to comply with penile rehabilitation.
  • Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  • Patients who are unable to understand the aims and objectives of the trial.
  • Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  • Currently taking medications which could affect graft incorporation (supervising physician's discretion).
  • Allergic to gentamicin and/or streptomycin.
  • Damage to neurovascular bundles during surgery.

结局指标

主要结局

The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.

时间窗: 4 weeks

次要结局

  • Time to return of erectile function.(Up to 6 months)
  • Pain scores.(10 days, 4 weeks, 3 months, and 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验